Search Results (197)

Over the past decades, gut microbiota has emerged as a critical modulator of human health and disease. Pregnancy involves substantial microbiota remodelling that influences offspring development, yet mechanisms linking maternal microbiota changes to gestational diabetes mellitus (GDM) remain unclear. The current literature lacks a comprehensive synthesis of pregnancy microbiota dynamics across healthy gestation to GDM, comparative human–murine analysis, and pregnancy-specific mechanistic frameworks distinct from type 2 diabetes models. This narrative review comprehensively synthesised evidence on gut microbiota composition in healthy pregnancy and GDM (2005–2025, NCBI PubMed) to identify convergent signatures and articulate pregnancy-specific mechanisms. Early pregnancy microbiota resembles non-pregnant individuals, whereas late pregnancy exhibits increased lactic acid-producing bacteria and reduced Firmicutes-to-Bacteroidetes (F/B) ratios. GDM exhibits pathological dysbiosis with elevated F/B ratios and reduced Bifidobacterium. Critically, GDM butyrate-producer patterns diverge from type 2 diabetes, suggesting pregnancy-specific mechanisms beyond glucose homeostasis. Despite these insights, methodological heterogeneity and cross-sectional designs constrain definitive conclusions. Longitudinal studies with standardised sequencing are essential to confirm consistent signatures and enable rational design of microbiota-modulating interventions (prebiotics, probiotics, synbiotics, postbiotics, diet) to optimise maternal health, prevent GDM, and support offspring development. Full article

The origin of life is, to the best of our knowledge, impossible to imagine without the formation of complex prebiotic biomolecules such as RNA, DNA, proteins and lipids. Lipids play a crucial role in the spontaneous formation of cell membranes, which are responsible for cell integrity, compartmentalization, selective permeability, and providing a microenvironment for biochemical reactions. The goal of the current work is to summarize the current state of the art regarding the abiotic formation of membrane building blocks, such as glycerol, fatty acids, and their phosphorylated version as phospholipid precursors. We describe the necessity of a systems chemistry approach for the complexification and expansion of the prebiotic network, enabling the formation of several membranogenic precursors. We also discuss prebiotic pathways for phosphorylation and acylation that could lead to phospholipid availability in hydrothermal environments and on the early Earth surface. We conclude with the possible spontaneous vesiculation of these molecules as a primitive version of the cell membrane. Thus, we present a comprehensive perspective on prebiotic vesicle formation, starting from simple molecules and developing until the self-assembly of vesicles. Full article

Cancer remains a leading cause of death worldwide, and current treatments are often limited by toxicity and resistance. Emerging research highlights the crucial roles played by gut microbiome dysbiosis and oxidative stress in cancer development and treatment response. Through their antioxidant, anti-inflammatory, and immunomodulatory properties, natural antioxidants such as resveratrol, along with microbiome modulators like probiotics, prebiotics, and synbiotics, offer promising therapeutic benefits. However, issues such as low bioavailability, instability, and challenges related to targeted delivery hinder the clinical translation of these bioactive compounds. Next-generation hydrogels have emerged as adaptable platforms capable of delivering and protecting these agents in a site-specific and controlled manner. This review summarizes the design and synthesis of multifunctional hydrogels incorporating natural antioxidants and microbiome modulators for cancer therapy. Full article

This study investigated the effect of low-cost carbon and nitrogen sources on fructosyltransferase (FTase) production by Aspergillus oryzae IPT-301, aiming to optimize the enzymatic synthesis of fructooligosaccharides (FOS), prebiotic compounds valued for their bifidogenic effects. FTase is a key enzyme in transfructosylation, the central step in FOS production. To reduce production costs, Very High Polarization (VHP) and Demerara (DM) sugars were evaluated as carbon sources, while sodium nitrate (NaNO₃), ammonium sulfate (NH₄)₂SO₄, and urea were tested as nitrogen sources. FTase production, both extracellular and intracellular, was conducted under submerged fermentation at 30 °C and 200 rpm for 72 h. DM sugar outperformed VHP, increasing extracellular and intracellular transfructosylation activity (A_T) by 2.3-fold and 2.1-fold, respectively. Among nitrogen sources, NaNO₃ was most effective in DM-containing media, yielding 1.6–2.0 times higher extracellular A_T and up to 4.7 times greater intracellular activity compared to other nitrogen sources. These findings suggest that the combination of DM sugar and NaNO₃ significantly enhances FTase yield, providing a cost-effective strategy for industrial-scale FOS production. Full article

Fructooligosaccharides (FOSs) are plant-based prebiotics widely utilized in the food and pharmaceutical industries. As a major sugar-producing region, Guangxi holds significant potential for enzymatic production of FOS from sucrose. This study engineered a mutant enzyme, 142P-242K, to address the low catalytic activity characteristic of wild-type enzymes. The mutation upregulated the FOS conversion efficiency from 29 to 52%, respectively. Optimal enzymatic activity was observed at 45 °C, pH 6.0, and in the presence of 1 mM Na⁺. Mechanistic investigations revealed that modifications to the catalytic domain pocket and shifts in substrate affinity were the primary factors driving enhanced FOS production. The accumulation of 1-Kestose (GF2) was attributed to the enhanced flexibility of the 142P-242K loop, which facilitates substrate access to the active site. However, the synthesis of nystose (GF3) from GF2 is hindered by the hydrophobic nature of the active site and strong hydrogen bonds binding GF2. Comparing the enzyme’s ability to produce FOS using sugarcane juice, sugarcane molasses, and adsorption-heating sugarcane molasses, it was determined that heat-adsorbed molasses yielded the highest FOS concentration (30.77%). This study offers a practical and cost-effective strategy for enzyme modification and efficient valorization of molasses. Full article

Background: Migraine is a highly prevalent and disabling primary headache disorder frequently accompanied by gastrointestinal symptoms and comorbid gastrointestinal diseases. Increasing evidence suggests that alterations in the gut microbiota and dysregulation of the microbiome–gut–brain axis may contribute to migraine pathophysiology through immune activation, oxidative stress, impaired intestinal barrier function, and neuroinflammatory signaling. Objectives: This narrative review aims to summarize current mechanistic and clinical evidence linking the gut–brain axis to migraine, with a particular focus on the potential roles of probiotics, prebiotics, and postbiotics as adjunctive strategies in migraine management. Methods: A narrative synthesis of experimental, translational, and clinical studies was performed, focusing on microbiome composition, gut barrier integrity, immune and oxidative pathways, and interventional trials evaluating probiotics, prebiotics, synbiotics, and microbiota-derived metabolites in adult and pediatric migraine populations. Results: Migraine has been associated with intestinal dysbiosis, increased gut permeability, and low-grade systemic inflammation. Probiotics, most commonly strains of Lactobacillus and Bifidobacterium, may modulate inflammatory cytokine profiles, enhance tight junction integrity, reduce oxidative stress, and influence neurotransmitter-related pathways along the gut–brain axis. Clinical trials evaluating probiotic supplementation report heterogeneous but promising signals, including reductions in migraine frequency, severity, disability scores, and analgesic use, particularly in chronic migraine and pediatric populations. Emerging evidence also supports a potential role for prebiotics (e.g., inulin-type fructans) and microbiota-derived metabolites such as short-chain fatty acids, although direct clinical data remain limited. Conclusions: Modulation of the microbiome–gut–brain axis represents a biologically plausible adjunct approach in migraine management. While probiotics, prebiotics, and postbiotics show potential benefits with favorable safety profiles, current evidence of their strain-, formulation-, and population-specific characteristics is lacking. Well-powered, placebo-controlled trials with standardized migraine endpoints and integrated microbiome and metabolomic analyses are needed to define responders, optimal interventions, and clinical relevance. Full article

Intestinal aging is characterized by a gradual decline in epithelial renewal capacity, barrier function, immune balance, and metabolic regulation, often accompanied by shifts in gut microbial composition. Polyamines, including putrescine, spermidine, and spermine, are vital microbial–host metabolites that support intestinal cell growth, autophagy, immune modulation, and mucosal repair. With advancing age, both host-derived and microbiota-mediated polyamine production declines, contributing to intestinal dysfunction and heightened vulnerability to inflammation and age-related disorders. This review explores the diet–microbiota–polyamine axis as a key biological framework influencing intestinal aging. It aims to integrate evidence on how dietary components and functional foods shape gut microbial ecology and, in turn, regulate microbial polyamine biosynthetic pathways that impact intestinal health. The review highlights major microbial contributors to polyamine metabolism, particularly lactic acid bacteria, and outlines mechanistic pathways linking polyamines to epithelial regeneration, inflammatory control, and gut barrier maintenance. It further discusses how age-associated dysbiosis disrupts these interactions and evaluates nutritional and microbial-based strategies such as fermented foods, prebiotics, and probiotics that may enhance polyamine availability and restore gut homeostasis. From the standpoint of food microbiology and human physiology, this synthesis underscores the translational potential of targeting microbial polyamine production through diet-based interventions. This article presents a narrative review synthesizing experimental, animal, and emerging human evidence on microbial and dietary polyamines in intestinal aging. In conclusion, modulating the diet–microbiota–polyamine axis represents a promising strategy to promote healthy intestinal aging, meriting deeper mechanistic exploration and validation through clinical studies. Full article

Fructooligosaccharides (FOS) represent a major source of prebiotic compounds. They are widely used in functional foods for their ability to modify intestinal microbiota in animals and humans. To address the significant issue of fructooligosaccharide production being influenced by glucose concentration, this study designed a dual-enzymatic co-catalysis system for glucose isomerase (GI) and a mutant FTase (FTase^142P-242K). This system successfully increased the FOS synthesis rate (42.31 to 55.51%, w/w). Glucose isomerase catalyzes the isomerization of glucose to fructose, and the subsequent release of fructose from the active site permits the enzyme to re-enter its catalytic cycle. The optimal conditions for catalysis were found at 45 °C, pH 5.5, and 1 mM Ba²⁺. In contrast, the optimal fermentation process was established at 25 °C and induction with 1 mM IPTG. Finally, the efficient production of FOS using low-cost byproduct molasses was achieved. Fermentation optimization of the dual-enzyme system resulted in FOS yield of 53.92% (w/w), a significant increase (44.54%, w/w) from the yield obtained using single-enzyme catalysis. Based on the research, a novel and sustainable approach for high-yield synthesis of Fructooligosaccharides involves minimizing the inhibitory effect of glucose produced during sucrose transformation. Full article

Carrot juice processing generates large amounts of pomace, a fibre-rich by-product with significant valorisation potential. This study explored the feasibility of fermenting carrot by-product with Levilactobacillus brevis AM7 and Leuconostoc pseudomesenteroides DSM20193 to produce exopolysaccharide (EPS)-enriched functional beverages. Beverages were fermented with or without sucrose addition (EPS⁺ and EPS⁻, respectively) and characterized for microbiological, biochemical, rheological, and sensory attributes. Both strains showed robust growth (>8 log cfu/mL) and acidification (final pH below 4.8), comparable to plant-based yoghurt alternatives, with EPS synthesis markedly enhanced in sucrose-supplemented beverages. Leuc. pseudomesenteroides DSM20193 synthesized the highest EPS concentration (16.8 g/100 g dry weight), resulting in a 6-fold viscosity increase compared to EPS⁻ samples, thus improving the adherence to the spoon and preventing syneresis of the beverages. Sensory evaluation revealed that EPS⁺ carrot-based beverages had improved sweetness due to a slight sucrose residue, aroma, and mouthfeel, while maintaining low off-flavours and high colour uniformity. The results highlight carrot by-product as a promising substrate for developing clean-label beverages that are rich in dietary fibres and polyphenols and show antioxidant and potential prebiotic properties through sustainable fermentation processes. Full article

Background/Objectives: Prebiotics, which are non-digestible compounds that selectively modulate gut microbiota, are recognized for their potential to promote host health. Although their bifidogenic effect is well documented, a systematic synthesis of how this microbial modulation translates into clinical gastrointestinal (GI) and metabolic outcomes across diverse populations is needed. This review aims to integrate mechanistic insights with clinical evidence to elucidate the pathway from prebiotic structures to tangible health benefits. Methods: This comprehensive narrative review details the structural properties of major prebiotics (e.g., inulin, FOS, and GOS) that govern their fermentation and the production of short-chain fatty acids (SCFAs). To evaluate clinical efficacy, an analysis of 22 randomized controlled trials from the past decade was conducted, focusing on human studies that utilized ISAPP-recognized prebiotics as the sole intervention. Results: The analysis confirms that prebiotic supplementation consistently increased the abundance of beneficial bacteria (e.g., Bifidobacterium and Lactobacillus) and SCFA production. These changes are associated with significant clinical improvements, including enhanced stool frequency and consistency, strengthened intestinal barrier function, and modulated immune responses. Benefits have been documented in healthy individuals, children, the elderly, and those with conditions such as constipation, metabolic syndrome, and antibiotic-associated dysbiosis. However, significant inter-individual variability in response was evident, and the study designs showed notable heterogeneity in prebiotic type, dosage, and duration. Conclusions: Prebiotics are effective modulators of gut health, driving clinical benefits through selective microbial fermentation and SCFA production. The documented heterogeneity and variability highlight the need for future research to focus on personalized nutritional strategies. Key priorities include standardizing intervention protocols, elucidating dose–response relationships, integrating multi-omics data to link taxonomy to function, and exploring novel applications such as synbiotic formulations and gut–brain axis modulation. Full article

Background: The global livestock industry faces pressure to reduce antimicrobial usage while maintaining animal health and productivity. Non-pharmaceutical interventions (NPIs) including probiotics, prebiotics, phytogenics, essential oils, organic acids, and enzymes have emerged as alternatives to antibiotic growth promoters. Commercial success depends on consumer acceptance and willingness to pay (WTP) for products from animals raised using these approaches. Objective: This systematic review synthesized peer-reviewed literature examining consumer knowledge, attitudes, perceptions, and WTP toward animal products produced using NPIs or marketed as antibiotic-free (ABF) to identify a critical gap in existing research. Methods: Following PRISMA 2020 guidelines, four databases (PubMed, Web of Science, Scopus, and Google Scholar) were searched for peer-reviewed studies published from January 2020 to December 2024. Inclusion criteria encompassed original research examining consumer perspectives toward NPIs or antibiotic-free (ABF) animal products. Narrative synthesis was employed due to study heterogeneity. Results: From 847 records, 15 studies met inclusion criteria. A critical finding was that virtually no peer-reviewed research directly examines consumer perceptions of specific NPIs such as probiotics, prebiotics, phytogenics, organic acids, or enzymes as feed additives. The included studies predominantly examined ABF production generally (60%) without specifying alternatives employed. Europe accounted for 80% of studies, while Asia accounted for 20%. Consumer awareness of agricultural antibiotic use was consistently low across contexts. Attitudes toward ABF products were favorable with one study reporting WTP premiums of 18–20%. Health consciousness was the strongest predictor of acceptance. Conclusions: The review highlights that while substantial literature exists on ABF products, no studies examine consumer perceptions of specific non-pharmaceutical interventions. Future research should investigate consumer responses to intervention specific labeling and communication strategies. Full article

The interplay between the oral and gut microbiota and systemic health has garnered significant attention in recent years, particularly concerning hematological malignancies. Multiple myeloma and other hematological cancers are characterized by immune dysfunction, creating a bidirectional relationship with microbial communities. Dysbiosis, defined as an imbalance in microbial composition, may influence disease progression, treatment response, and overall prognosis. This narrative review is based on a non-systematic search of PubMed and Scopus (2010–2024) using terms related to oral microbiota, gut microbiota, dysbiosis, hematological malignancies, multiple myeloma, immune modulation, and treatment-related complications. Studies were selected for relevance to pathogenesis, immune regulation, clinical implications, and therapeutic interactions. As this is a narrative review, no quantitative synthesis or formal grading of evidence strength was performed; findings are therefore interpreted qualitatively based on the available literature. The role of microbial-derived metabolites, their effects on immune modulation, and their potential as biomarkers for disease and treatment outcomes have been explored. Specific attention is given to the implications of dysbiosis in chemotherapy-induced complications, such as mucositis and infections, and emerging therapeutic strategies, including probiotics, prebiotics, and fecal microbiota transplantation. Additionally, the influence of anticancer therapies on microbial ecosystems has been highlighted and the bidirectional impact of host–microbe interactions in shaping disease trajectory has been discussed. Understanding these complex interactions could lead to novel diagnostic and therapeutic approaches, ultimately improving patient outcomes. This review aims to provide clinicians and researchers with a comprehensive overview of current knowledge and future perspectives on the role of oral and gut microbiota in the context of hematological malignancies. Full article

Boron (B) remains one of the least understood trace elements in human nutrition. Traditionally regarded as non-essential, its biological role has been reevaluated in light of emerging microbiome research. We provide a narrative synthesis of mechanistic, preclinical, and clinical studies to assess whether the colonic actions of B meet accepted criteria for nutritional essentiality. This review revisits B bioavailability through a dual-pathway framework distinguishing plasma-accessible boron (PAB)—small, fully absorbable species with transient systemic effects—from microbiota-accessible boron complexes (MABCs)—indigestible conjugates that reach the colon intact. Evidence indicates that PAB exerts short-term metabolic modulation, whereas MABCs act as prebiotic cofactors that stabilize microbial quorum sensing (autoinducer-2–borate; AI-2B), reinforce the colonic mucus barrier through borate–diol crosslinking, and support host–microbiota symbiosis. Deficiency or low intake of MABCs leads to dysbiosis, barrier fragility, and low-grade inflammation along gut–organ axes—effects reversible by MABC-rich diets. Analytical and clinical tools are proposed to discriminate between PAB and MABC pathways, including fecal B/speciation, AI-2B assays, and mucus-penetration markers. Recognizing B’s essentiality as a microbiota-dependent nutrient reframes its nutritional assessment, guiding future dietary guidelines and prebiotic design toward the microbiome–mucus interface. Full article

A multifaceted clinical disease, heart failure (HF) is typified by decreased cardiac function and systemic symptoms caused by anatomical or functional abnormalities in the heart. Although traditional studies have concentrated on hemodynamic and neurohormonal processes, new data highlight the vital role that the gut microbiota and its byproducts play in the pathogenesis of HF. An imbalance in the microbial structure known as gut dysbiosis is common in HF patients and is linked to increased gut permeability, systemic inflammation, and changed bioactive metabolite synthesis. Prominent metabolites generated by the microbiota, including phenylacetylglutamine, short-chain fatty acids (SCFAs), secondary bile acids, and trimethylamine N-oxide (TMAO), have a major impact on endothelial function, cardiac remodeling, and inflammation. Together with gut-derived lipopolysaccharides, these metabolites interact with host systems to exacerbate the course of HF. Further impacting HF outcomes are comorbidities such as diabetes, obesity, and chronic renal disease, which intensify gut dysbiosis. The importance of metabolites originating from the microbiota in the progression of HF is highlighted in this review, which summarizes recent findings regarding the gut-heart axis. Additionally, it investigates how dietary changes, probiotics, prebiotics, and multi-omics techniques can all be used to improve the management of HF. This thorough analysis emphasizes the necessity of integrative therapy approaches and longitudinal research to better address the complex link between HF and the gut microbiota. Full article

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are highly effective in the management of obesity; however, their efficacy and tolerability may be further optimized through complementary nutritional strategies. Such interventions may address key challenges associated with GLP-1RA therapy, including gastrointestinal adverse effects, lean mass loss, and reduced long-term adherence leading to weight regain. Evidence from preclinical and clinical studies indicates that omega-3 polyunsaturated fatty acids may enhance the metabolic benefits of GLP-1RAs and attenuate lean mass loss, primarily via anti-inflammatory pathways and modulation of protein synthesis. Synergistic effects have also been reported with other bioactive compounds—such as flavonoids and anthocyanins, which improve metabolic outcomes; probiotics and prebiotics, which may alleviate gastrointestinal intolerance; and high-quality protein sources, which support body composition preservation. Collectively, these findings suggest that nutritional adjuncts may complement GLP-1RA therapies through convergent physiological mechanisms, including the regulation of inflammation, gut microbiome composition, and cellular metabolism. While current data highlight the promise of integrated pharmaco-nutritional strategies as adjuncts to GLP-1-based obesity therapy, further randomized controlled trials are needed to establish the most effective interventions and protocols. Full article